Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

August 1, 2025

Conditions

Acute Heart Failure

Interventions

DRUG

Dapagliflozin 10mg

Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

DRUG

Acetazolamide 500mg

Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.

Trial Locations (1)

RECRUITING

Noha Mansour, Al Mansurah

All Listed Sponsors

lead

Mansoura University

OTHER